GeoVax Labs, Inc.
No enriched coverage for $GOVX in the last 7 days.
No SEC Form 4 filings for $GOVX in the last 30 days.
GeoVax Labs, Inc. announced a warrant inducement transaction with institutional investors. These investors will exercise existing warrants for approximately $595,000 in gross proceeds and, in return, receive new unregistered warrants to purchase up to 1,002,288 shares of common stock at $1.65 per share. The new warrants will become exercisable after shareholder approval and expire five years later.
GeoVax Labs, Inc. has entered into a warrant inducement agreement with existing institutional investors. This agreement involves the immediate exercise of existing warrants for approximately $595,000, with the company providing new unregistered warrants to purchase up to 1,002,288 shares of common stock. The net proceeds will be used for working capital and general corporate purposes, with the transaction expected to close around May 8, 2026.
GeoVax Labs, Inc. announced its financial results for 2025 and provided an update on its lead vaccine candidate, GEO-MVA, for mpox and smallpox. The company plans to initiate a pivotal Phase 3 clinical trial for GEO-MVA during the second half of 2026, aiming to address critical global supply shortages and public health preparedness needs for orthopoxvirus vaccines. GeoVax highlighted significant milestones, including regulatory alignment with the European Medicines Agency and manufacturing readiness.
